Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2013. The report details a specific share repurchase transaction executed on November 1, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 243,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,654.50 pence per share; lowest price paid was 1,628.00 pence per share.
- Treasury Holdings (Settled): 507,894,912 shares (9.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,442,412 shares (10.46% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,862,445,368 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 243,500 shares for treasury. Consequently, the percentage of total voting rights held in treasury increased to 10.46% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a routine disclosure of a share repurchase activity and confirms compliance with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in treasury (507,894,912 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.46% treasury ownership calculation.
- Check the settlement status of the 547,500 shares (difference between settled and total treasury holdings) to confirm the 10.46% voting rights figure.
- Review the price paid (1,628.00 to 1,654.50 pence) against the market price on November 1, 2013.